Organization | American Scitech International

American Scitech International Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2010

NCT00725400

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Alternative names

American Scitech International | American Scitech International- eCRO

Active Ingredients

Drugs in Phase 3 Trials (5)

bleomycin (blenoxane) (2 trials)

dacarbazine (dtic-dome) (2 trials)

doxorubicin (Doxil) (2 trials)

rituximab (rituxan) (2 trials)

vinblastine (velban) (2 trials)

Drugs in Phase 2 Trials (2)

cetuximab (erbitux) (1 trial)

platelet derived growth factor (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Burns (Phase 2)

Burns, Electric (Phase 2)

Hodgkin Disease (Phase 3)

Lymphoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 7